Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients

Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients

Abstract Background In 2019, more than 30 % of all newly transplanted kidney transplant recipients in The Netherlands were above 65 years of age. Elderly patients are less prone to rejection, and death censored graft loss is less frequent compared to younger recipients. Elderly recipients do have in...

Full description

Bibliographic Details
Main Authors: S. E. de Boer, J. S.F. Sanders, F. J. Bemelman, M. G.H. Betjes, J. G.M. Burgerhof, L. Hilbrands, D. Kuypers, B. C. van Munster, S. A. Nurmohamed, A. P.J. de Vries, A. D. van Zuilen, D. A. Hesselink, S. P. Berger
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Nephrology
Subjects:
Elderly kidney transplant recipients
Reduced CNI exposure
mTOR inhibitor
Everolimus
(Health-related) quality of life
Patient-reported outcomes
Online Access:https://doi.org/10.1186/s12882-021-02409-8

Internet

https://doi.org/10.1186/s12882-021-02409-8

Similar Items